Phase III Study of Z-206
Phase 3
- Conditions
- lcerative Colitis
- Registration Number
- JPRN-jRCT2080222089
- Lead Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Those who are with ulcerative colitis in remission state
etc.
Exclusion Criteria
-Those who have a history of drug hypersensitivity to mesalazine or salicylic acid series
etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of patients without relapse
- Secondary Outcome Measures
Name Time Method The time to relapse